ABSTRACT: Argonaute proteins are the core components of the microRNP/RISC. The biogenesis and function of microRNAs and endoand exo-siRNAs are regulated by Ago2, an Argonaute protein with RNA binding and nuclease activities. Currently, there are no in vitro assays suitable for large-scale screening of microRNP/RISC loading modulators. We describe a novel in vitro assay that is based on fluorescence polarization of TAMRA-labeled RNAs loaded to human Ago2. Using this assay, we identified potent small-molecule inhibitors of RISC loading, including aurintricarboxylic acid (IC 50 = 0.47 μM), suramin (IC 50 = 0.69 μM), and oxidopamine HCL (IC 50 = 1.61 μM). Small molecules identified by this biochemical screening assay also inhibited siRNA loading to endogenous Ago2 in cultured cells. R NA interference (RNAi) depends on double-stranded RNA and induces sequence-specific gene silencing.
The endogenous RNAi pathway intersects with the microRNA (miRNA) machinery, which in mammals regulates gene expression by inhibiting protein synthesis and inducing mRNA decay. 4, 5 Endo-and exo-siRNAs and miRNAs are processed in the cytoplasm by the RNase III enzyme Dicer and loaded to Ago proteins to form effector complexes (microRNP or RISC). Endo-siRNAs modulate innate immunity in plants, 6 −8 Drosophila, 9, 10 and C. elegans. 11−13 Although the function of mammalian endo-siRNAs is not yet understood, it is likely that they operate primarily in oocytes, 14, 15 where miRNA function appears to be non-essential. 16 In contrast to the elusive function of mammalian endo-siRNAs, somatic miRNAs in mammals regulate numerous biological processes, and their disordered expression has been linked to human diseases. 17 In the past decade, RNAi directed by exogenously administered small RNAs emerged as a powerful molecular tool for gene-specific studies, complementing classic genetic approaches. Like miRNAs and endo-siRNAs, exogenous siRNAs are incorporated into Ago complexes. 18 Ago2 is an RNA-guided endonuclease with the ability to form catalytically active complexes with siRNAs/miRNAs and their precursors. 18−22 In addition to its RNA binding and catalytic activity, Ago2 competes with the cellular translation machinery 23−25 to halt translation initiation. Ago2 has been implicated in the biogenesis of siRNAs 26 and of miRNA subsets, either by Dicerindependent processing of miRNA precursors 27−29 or by mechanisms that are not yet clearly understood. 30, 31 Due to its role as regulator, carrier, and executor of miRNA/siRNA function, Ago2 is at the core of the RNAi, and its regulation directly affects the biology of miRNAs and siRNAs, at multiple layers.
Recently, novel approaches have emerged for the identification of chemical modulators of miRNAs. In this limited number of recent studies, cell-based assays have been the predominant methodology for large-scale screenings of compounds that enhance or inhibit miRNAs or siRNAs. 32−36 In general, these assays do not permit identification of RNAi pathway components directly affected by the modulators. With the exception of a recent report demonstrating inhibition of Dicer's function by small molecules, 33 in vitro assays utilizing purified recombinant RISC factors have not been previously reported.
In this study, we describe a novel method for large-scale screening of chemical compounds that interfere with RISC loading. In order to identify potential RISC modulators, we used purified recombinant Ago2 to screen two collections of small compounds: the Library of Pharmacologically Active Compounds (LOPAC) and a custom collection of compounds from the National Institute of Neurological Disorders and Stroke (NINDS). Our studies established a novel in vitro method that is based on fluorescence polarization (FP) of TAMRA-labeled small RNAs and identified molecules that inhibit RISC loading in vitro. Further testing using cell-based assays demonstrated that compounds identified by large scale in vitro screenings also inhibit de novo assembly of endogenous RISC.
■ RESULTS AND DISCUSSION
Small Molecule Inhibition of in Vitro RISC Reconstitution: Results of LOPAC and NINDS Compound Libraries Screening. A total of 1,280 compounds from the LOPAC library (final screening concentration 100 μM) and a custom collection of 1,040 compounds (final screening concentration 20 μM) from the National Institute of Neurological Disorders and Stroke (NINDS) were screened for potential inhibitors of miR-21 and Ago2 binding. The assay is described in Methods and illustrated in Figure 1A . The average Z-factor for the screening was ∼0.6, indicating a robust assay. 37 A representative Z-factor plot is shown in Figure 1B . Setting a 40% inhibition as a cutoff point, we detected 46 hits from the LOPAC (hit rate 3.6%) and 21 hits from the NINDS library (hit rate 2%). All hits were subjected to a 16-point, 2-fold serial dilution (final concentration 50−0.0015 μM) dose− response testing to determine the IC 50 for Ago2:miR-21 binding inhibition. With confirmation dose−response testing of the high-throughput screening (HTS) hits, a total of 17 compounds from the LOPAC and 8 compounds from the NINDS library showed an IC 50 < 50 μM (confirmation rate of 37%).
DNA Binding Assays. To exclude nonspecific DNAbinding inhibitors, we next performed a counter screen of the candidate compounds that were confirmed in the dose− response test. In this assay, compounds were tested for competition of ethidium bromide (EtBr) binding to DNA (average Z-factor of 0.81). Compounds with IC 50 < 50 μM in the EtBr competition assay were then excluded because their activity in the Ago2:miR21 FP assay was considered a result of nonspecific nucleic acid binding. After filtering out compounds that were DNA binders, 12 confirmed hits from the LOPAC and 6 confirmed hits from the NINDS library remained. Three compounds with the lowest IC 50 Normalized RL expression analysis revealed a robust derepression of RL by ATA and modest de-repression by suramin sodium salt ( Figure 3A ). Oxidopamine HCL in the concentration used had no effect on RL expression. Since ATA was a potent inhibitor of siRNA activity in cell-based assays, we next performed a dose−response experiment. Cells were treated with ATA at concentrations ranging from 6.25 to 50 μM. Optimal de-repression of RL was achieved at concentration of 25 μM. At higher concentrations (50 μM), the efficiency of de-repression decreased, likely indicating a saturation effect ( Figure 3B ). Next, we tested if ATA interferes with siRNA inhibition of an endogenous gene using an siRNA that targets RNA helicase A (RHA). We showed that in mouse embryonic fibroblasts, ATA de-represses siRNA knockdown of RHA ( Figure 4 ). Together, these results indicate that ATA inhibits RISC activity against transiently expressed reporters and endogenous genes.
ATA Inhibits siRNA Loading to Endogenous Ago2. We next examined the effect of ATA on the RNA binding and nuclease activity of endogenous Ago2, in order to determine whether ATA also inhibits RNA loading to Ago2 in cultured cells. The RNA binding and catalytic activities of endogenous Ago2 were tested in 293TRex cells treated with ATA or oxidopamine HCL. The association of endogenous miRNAs to Ago2 and the RISC activity of immunoprecipitated endogenous Ago2 complexes were comparable in cells treated with ATA or oxidopamine HCL ( Figure 5A and B) . Interestingly, while endogenous miRNA:Ago2 complexes were not perturbed, loading of exogenous siRNA (siLuc) to Ago2 was completely inhibited by ATA ( Figure 5A ). These results are consistent with those from our in vitro screening using recombinant Ago2 and indicate that ATA inhibits RNA binding to endogenous Ago2 and de novo RISC assembly, without disturbing preformed complexes of Ago2 with endogenous small RNAs or inhibiting the catalytic activity of Ago2.
Recent studies have identified chemical modulators of miRNAs and siRNAs 32−36,38 utilizing cell-based assays. Enoxacin has been shown to promote the biogenesis of miRNAs and to enhance their function. 34 In addition, inhibitors and enhancers of miR-122, a miRNA required for hepatitis C replication by the liver, have been recently reported. 36 In vitro,
Dicer processing of synthetic shRNAs modified to contain Gquadruplexes is inhibited by porphyrazines and bisquinolinium compounds. 33 In vitro assays utilizing purified, minimal RISC have not been reported previously.
In our study, we undertook a novel approach by taking advantage of our previously described in vitro RISC reconstitution assay. 21, 22 We established a robust in vitro methodology to screen large chemical compound libraries for modulators of RISC, by testing the binding of TAMRA-labeled miR-21, a miRNA implicated in pathways controlling cell proliferation and apoptosis, 39 to recombinant Ago2. Aurintricarboxylic acid (ATA), oxidopamine HCL, and suramin sodium salt reproducibly inhibited in vitro RISC reconstitution.
Suramin is a purinoceptor antagonist 40 with antihelminthic and antiprotozoal activity. 41 It inhibits the activity of deoxyribonucleic/ribonucleic acid (DNA/RNA) polymerase and human immunodeficiency virus (HIV) reverse tran- scriptase in vitro. 42 In our studies, suramin inhibited the binding of miR-21 to Ago2 in vitro and had a modest effect in cell-based assays.
Oxidopamine HCL is an adrenergic agent that has been used extensively for the depletion of dopaminergic neurons and experimental induction of Parkinson-like syndrome in animals. 43 The molecular mechanisms of oxidopamine HCL function are not well understood. 44 Although it potently inhibited miR-21 loading to Ago2 in vitro, oxidopamine did not interfere with loading of siRNA to endogenous RISC in cellbased assays.
ATA is a triphenyl-methyl molecule that inhibits nucleases and nucleic acid-binding enzymes. 45, 46 When administered to mice, ATA inhibits infectivity and replication of T cell viruses at concentrations that are not toxic to the host cell. 47 It was recently shown that ATA is a potent inhibitor of human flap endonuclease inhibitor 1 (FEN1). 48 In vitro, as well as in cellbased assays, ATA potently inhibited the loading of small RNAs to Ago2. This inhibition was not sequence-specific, as indicated by our experiments using three different RNAs (miR-21, siLuc, and siRHA). Importantly, at the concentrations used in this study, ATA blocked loading of siRNAs to endogenous Ago2 without affecting the nuclease activity of the protein or dissociating preformed Ago2 microRNPs. This implies that ATA targets RNA-free Ago2, either by inducing conformational changes or, more likely, by directly blocking the RNA binding domains of the protein. Preformed microRNPs are not affected, likely because miRNAs bound to Ago2 preclude direct interaction of ATA with the protein.
Our studies established a novel in vitro assay for highthroughput screening (HTS) of chemical modulators of RISC. This fluorescence polarization (FP) assay is simple, utilizes the minimal RISC components, and can be readily used for largescale screenings. Since the assay allows for testing of individual miRNA/siRNA loading to Ago2, it can be used to identify modulators of specific miRNAs/siRNAs. RNAi is widely used as a novel tool for studies of gene expression, regulation, and function. To our knowledge, this is the first report of a tool that can be used for high-throughput screening for modulators of the RNAi executor. Furthermore, Ago proteins are also the executors of the miRNA function. Thus our novel FP assay provides a tool for HTS of modulators of a key protein in the miRNA/siRNA pathway and can potentially have broad applications in studies of the function of Ago and individual miRNAs in cell biology and human disease.
Using our novel assay we identified ATA as a potent inhibitor of de novo RISC assembly in vivo and in vitro, which does not affect preformed endogenous miRNA complexes and does not inhibit the catalytic activity of Ago2. Thus, ATA can be used to study individual microRNPs or miRNAs, their halflives, and stability or to study the function of endogenous RNAfree Ago2. Such studies should be planned taking into consideration possible effects of the compounds on cell biology. For example, ATA is a generic nuclease inhibitor, with potentially deleterious effects at high concentrations. However, in the relatively low concentration of 25 μM, ATA selectively inhibits loading of siRNAs to Ago2 without affecting other functions of the protein. Previous studies have shown that ATA is associated with low toxicity in tissue cultures 49 and is well-tolerated in vivo. 50 For in vitro studies of RISC assembly using purified Ago2 and synthetic siRNAs, the direct effect of ATA on siRNA loading versus potential "adverse" effect on the nuclease activity of Ago2 can be assessed by different experimental methodologies.
In summary, we established a tool for HTS of microRNP/ RISC modulators and identified compounds that can be used to block the cycle of miRNA loading to Ago2, with applications in RNAi and in studies of the biogenesis and function of miRNAs in different tissues and cell lines.
■ METHODS
Expression and Purification of GST-Ago2. Recombinant mouse Ago2 was purified and tested for RISC activity as described in ref 22 .
High-Throughput Small Molecule Screening Assay. Volumes of 1 μL of miRNA buffer (40 mM CH 3 COOK, 4 mM MgCl 2 , 1 mM DTT), 0.5 μL RNasin Ribonuclease Inhibitor, and 2.5 μL RNase-free water were dispensed into each well of 384-well assay plates. After pintool transfer of 100 nL of compound from DMSO compound plates (with pure DMSO in control columns) to the assay plate, a volume of 2 μL of TAMRA labeled miR-21 and 4 μL of GST-Ago2 were added separately to each well at a final concentration of 3.75 nM and 150 ng respectively, in the 10 mL final reaction volume. Columns 1 and 23 of each 384-well plate received 4 μL of water instead of GSTAgo2 to provide the minimum polarization value for each plate. Columns 2 and 24 received 100% DMSO instead of a chemical compound in order to determine the highest polarization signal for full binding of the fluorescent miR-21 by GST-Ago2. The means and standard deviations of the "no-Ago2" control columns 1 and 23 and the "DMSO" control columns 2 and 24 were used to calculate the Zfactor for each plate to estimate the robustness of the assay ( Figure  1B) . The assay plates were incubated at RT for 30 min and fluorescence polarization was measured (EnVision, PerkinElmer) to calculate the millipolarization units (mP) [(mP = 1000(S − GP)/(S + GP)]; mirror: BODIPY TMR FP Dual, excitation filter: BODIPY TMR FP 531 nm, G = instrument factor, P = signal from PerkinElmer BODIPY TMR FP P-pol 579 nm first emission filter, S = signal from PerkinElmer BODIPY TMR FP S-pol 579 nm second emission filter). A value of 3 × standard deviation was used to set the cutoff point to select hits. Each hit from the primary HTS screen was then tested twice using a 16-point, 2-fold dilution (final concentration 50−0.0015 μM) dose−response assay to determine the IC 50 Cell Culture, Transfection, and Luciferase Assays. T-REx 293 (Invitrogen) cells were cultured with Dulbecco's Modified Eagle Medium (DMEM) (Invitrogen) supplemented with 10% FBS (Sigma) and L-glutamine (Mediatech). Cells were cultured in 100-mm dishes and transfected at 40% confluency with 0.5 μg of pRLTK and 2 μg of pGL3 plasmids, using Lipofectamine 2000 (Invitrogen). Twenty-four hours after transfection, 3 × 10 5 cells/mL were transferred to 6-well plates and treated with 25 μM oxidopamine HCL (Sigma, H4381), aurintricarboxylic acid (ATA) (Sigma, A1895), suramin sodium salt (Sigma, S2671), or DMSO (Fisher) for additional 24 h. Treated cells were then transfected with Silencer Renilla Luciferase siRNA (AM4630) or Silencer Negative Control no. 1 siRNA (AM4611) in Opti-MEM (Invitrogen) using Lipofectamine RNAiMax (Invitrogen). Transfection media contained each of the above compounds at 25 μM concentration. Twenty-four hours after siRNA transfection, cells were harvested for Luciferase assays or immunopreciptation and Northern blot. Luciferase assays were performed as described. 51, 52 For RHA RNAi, mouse embryonic fibroblasts (MEFs) were first treated with ATA (25 μM) or DMSO for 24 h, as described above. Treated mEFs were then transfected with of RHA siRNA (25 μM, Dharmacon ON-TARGETplus SMARTpool DHX9 no. L-056729) for an additional 48 h. Cells were harvested, and RHA protein was detected by Western blot (RHA antibody: Abcam, ab26271, 1:1000). β-Tubulin was used for loading normalization (E7 ascites: Developmental Studies Hybridoma Bank, 1:2000) .
RNA Immunoprecipitation, RISC Activity Assay, and Western and Northern Blot. For RNA immunoprecipitation (RIP), cells were lysed in buffer containing 20 mM Tris-HCl, pH 7.4, 200 mM sodium chloride, 2.5 mM magnesium chloride, and 0.5% Triton X-100, and endogenous miRNPs were immunoprecipitated as described in ref 51 . Briefly, cell lysates were first mixed with 20 μL of protein G agarose beads (Invitrogen) preincubated with 5 μL of monoclonal anti-Ago antibody 2A8 53 or 0.5 μL of nonimmune mouse serum, at 4°C overnight. Agarose beads were then washed in lysis buffer. As described previously, 51 10% of total protein G agarose volume was used for Western blot, 10% for in vitro RISC assay, and 80% for Ago2-bound RNA isolation and Northern blot. For Ago2 detection by Western blot, 2A8 was used in 1:1000 dilution. In vitro RISC activity assays were performed with endogenous immunoprecipitated RISC complexes and a radiolabeled RNA target perfectly complementary to endogenous Let-7a-3 (TGLet7-a), as previously described. 22, 54 Northern blots were hybridized with a 5′-end radiolabeled DNA probe antisense to Renilla Luciferase siRNA (siLuc) at 37°C overnight or LNA probe antisense to Let7a at 42°C overnight, and hybridization signals were detected by autoradiography.
5′-End Labeling and Sequences of RNA, DNA, and LNA Oligonucleotides. RNA, LNAand DNA oligonucleotides were 5′-end radiolabeled with T4 polynucleotide kinase (NEB) as previously described. 51 Oligonucleotide sequences: TGLet7a: 5′-GUAUCAACCACUAUACAACCUACUACCU-CAACGUUCAAUC-3′
Renilla Luciferase siRNA (siLuc) DNA antisense: 5′-TAG-GAAACTTCTTGGCACC-3′
LNA-let-7a-3: 5′-AACTATACAACCTACTACCTCA-3′ 
